Analysis of gene expression levels and their impact on survival in 31 cancer-types patients identifies novel prognostic markers and suggests unexplored immunotherapy treatment options in a wide range of malignancies

Table 3 Survival in melanoma patients, according to the expression values, in melanoma GSE datasets (http://www.progtools.net/gene/index.php)

Gene	GSE*	HR (Hazard Ratio)	P value	Median survival in high express patients (days)	Median survival in low express patients (days)	Survival at 5 years in high express patients (%)	Survival at 5 years in low express patients (%)
CTLA4	19,234	0.8	0.5	3943	1096	61	50
PD-1 (PDCD1)	19,234	0.09	0.02	3943	1397	63	46
PD-L1 (CD274)	53,118	0.3	0.3	5481	3005	76	52
LAG3	19,234	0.35	0.009	4821	955	67	42
TIM3 (HAVCR2)	53,118	0.74	0.04	6899	3271	68	58
OX40 (TNFRSF4)	19,234	0.45	0.1	3943	2336	62	48
GITR (TNFRSF18)	53,118	0.19	0.05	6899	1734	81	46
TIGIT	19,234	0.45	0.01	NA**	817	71	40
4-1BB (TNFRSF9)	53,118	0.3	0.006	6899	3005	73	55

^*When data were available from more than one GSE, the one showing the highest difference in median survival is reported

ISSN: 1479-5876